详情页

当前位置：首页 > 详情页

A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [2]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [3]Hebei Canc Hosp, Shijiazhuang, Hebei, Peoples R China

出处：

ISSN：

关键词： Anlotinib Osimertinib ctDNA

语种：

WOS：

中科院分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2024]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 20.8 最新[2024版] 18.4 最新五年平均 21.1 出版当年[2023版] 16.5 出版当年五年平均 20.4 出版前一年[2022版] 20.8 出版后一年[2024版]

第一作者：

第一作者机构： [1]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis [2]Simultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/ MS [3]Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (ALTN-03) [4]Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (ALTER0303) [5]Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases [6]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405) [7]Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma [8]Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) [9]Transcriptomics Coupled with Proteomics Reveals Osimertinib-induced Myocardial Mitochondrial Dysfunction [10]Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection